MedPath

AN OPEN-LABEL, SINGLE ARM, MONOCENTRIC, PHASE I/II CLINICAL STUDY OF INTRACEREBRAL ADMINISTRATION OF ADENO-ASSOCIATED VIRAL VECTORS SEROTYPE 10 CARRYING THE HUMAN SGSH AND SUMF1 cDNAS FOR THE TREATMENT OF SANFILIPPO TYPE A SYNDROME - Intracerebral Gene therapy for Sanfilippo type A syndrome

Conditions
Sanfilippo type A syndrome (also named Mucopolysaccharidosis Type A)
MedDRA version: 12.1Level: LLTClassification code 10056918Term: Sanfilippo's syndrome
Registration Number
EUCTR2010-019962-10-FR
Lead Sponsor
SANFILIPPO Therapeutics SAS
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
4
Inclusion Criteria

•Age: 18 (eighteen) months to end of 6 (six) years
•Onset of clinical manifestations related to MPSIIIA during the first 5 years of life
•SGSH activity in peripheral blood cell and/or cultured fibroblast extracts of less than 10% of controls.
•Patient affiliated to the social security
•Family understanding the procedure and the informed consent
•Signed informed consent
•Vital laboratory parameters within normal range

Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

•Presence of brain atrophy on pre-inclusion MRI judged on a cortico-dural distance of more than 1cm
•No independent walking (Ability to walk without help)
•Any condition that would contraindicate permanently anaesthesia
•Any other permanent medical condition not related to MPSIIIA
•Any vaccination 1 month before treatment
•Receipt of aspirin within one month
•Any medication aiming at modifying the natural course of MPSIIIA given during the 6 months before vector injection
•Any condition that would contraindicate treatment with Prograf®, Cellcept® and Solupred®

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath